Although consistent with our in vitro observations about the independence of the results of the RAS/BRAF mutation status of the cell lines, clinical implications of the findings should be interpreted with caution, as cetuximab is typically avoided in the clinical practice for the treatment of the BRAF mutant cancer with relatively poor prognosis3. This evidence concerns the gene BRAF and cancer.